ELDN vs. IMMX, ANEB, TLSA, KZR, CALC, KRON, CKPT, CARM, EGRX, and AEON
Should you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Immix Biopharma (IMMX), Anebulo Pharmaceuticals (ANEB), Tiziana Life Sciences (TLSA), Kezar Life Sciences (KZR), CalciMedica (CALC), Kronos Bio (KRON), Checkpoint Therapeutics (CKPT), Carisma Therapeutics (CARM), Eagle Pharmaceuticals (EGRX), and AEON Biopharma (AEON). These companies are all part of the "pharmaceutical preparations" industry.
Immix Biopharma (NASDAQ:IMMX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
Immix Biopharma currently has a consensus price target of $14.00, indicating a potential upside of 506.06%. Eledon Pharmaceuticals has a consensus price target of $11.67, indicating a potential upside of 316.67%. Given Eledon Pharmaceuticals' higher possible upside, analysts plainly believe Immix Biopharma is more favorable than Eledon Pharmaceuticals.
11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 55.9% of Immix Biopharma shares are owned by company insiders. Comparatively, 19.4% of Eledon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Immix Biopharma's return on equity of -43.52% beat Eledon Pharmaceuticals' return on equity.
Eledon Pharmaceuticals received 21 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 71.43% of users gave Eledon Pharmaceuticals an outperform vote.
Immix Biopharma has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
Immix Biopharma is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Eledon Pharmaceuticals had 6 more articles in the media than Immix Biopharma. MarketBeat recorded 15 mentions for Eledon Pharmaceuticals and 9 mentions for Immix Biopharma. Eledon Pharmaceuticals' average media sentiment score of 1.15 beat Immix Biopharma's score of 0.66 indicating that Immix Biopharma is being referred to more favorably in the media.
Summary
Eledon Pharmaceuticals beats Immix Biopharma on 8 of the 14 factors compared between the two stocks.
Get Eledon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eledon Pharmaceuticals Competitors List
Related Companies and Tools
